Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON‐1 Study

The efficacy of the CD30‐directed antibody‐drug conjugate (ADC) brentuximab vedotin was established in combination with chemotherapy as frontline treatment for advanced classical Hodgkin's lymphoma in the randomized phase III ECHELON‐1 study. Population pharmacokinetic (PK) and exposure–respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Suri, Ajit, Mould, Diane R., Song, Gregory, Collins, Graham P., Endres, Christopher J., Gomez‐Navarro, Jesús, Venkatakrishnan, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896233/
https://www.ncbi.nlm.nih.gov/pubmed/31152605
http://dx.doi.org/10.1002/cpt.1530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896233/
https://www.ncbi.nlm.nih.gov/pubmed/31152605
http://dx.doi.org/10.1002/cpt.1530

Ejemplares similares